Minimal Residual Disease Endpoint Would Aid Leukemia Drug Development, Experts Say
Executive Summary
An international panel of hematology experts tells an FDA/ASCO workshop Feb. 27 that minimal residual disease would be a useful surrogate endpoint for assessing the effects of chronic lymphocytic leukemia therapies because it has been strongly correlated with longer-term outcomes in the disease.
You may also be interested in...
Cancer Trial Endpoints: Minimal Residual Disease Eyed As Surrogate
More work needs to be done to validate MRD as predictive of clinical outcomes in hematological malignancies before it can be used as the basis for accelerated approval, FDA and other stakeholders say.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.